» Articles » PMID: 2390477

1,2-dithiol-3-thione and Dithioester Analogues: Potential Radioprotectors

Overview
Journal Br J Cancer
Specialty Oncology
Date 1990 Jul 1
PMID 2390477
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Several 1,2-dithiol-3-thione and dithioester compounds were assayed for radioprotective capabilities in EMT6 cells in vitro. The 1,2-dithiol-3-thiones were generally more cytotoxic than the dithioesters and in some instances were more cytotoxic toward hypoxic cells than toward normally oxygenated cells. When the drugs were present at a concentration of 500 microM for 1 h prior to and during radiation delivery, the 5-(2-thienyl)-1,2-dithiol-3-thione produced a radiation protection factor (RPF) of 2.7 at 1 log of cell kill. The 4-methyl analogue of this same compound was, however, much less effective, producing a RPF of only 1.2. The 4-ethoxycarbonyl analogue was moderately active, producing a RPF of 1.7. The 4-methyl-5-(2-pyrazinyl)-1,2-dithiol-3-thione (Oltipraz) was least effective, yielding a RPF of only 1.1. Of the dithioesters tested, methyl 3-pyrrolidino-2-phenylpropene dithiocarboxylate produced a RPF of 2.6, methyl 3-piperidino-2-phenylpropenedithiocarboxylate a RPF of 2.7, and the corresponding 3-morpholino and 3-thiomorpholino derivatives RPF values of 2.7 and 2.9, respectively. The iodide salt of 4-ethoxycarbonyl-5-(2-thienyl)-1,2-dithiol-3-thione produced a RPF of 2.6 Methyl 3-cyclohexylamino-2-phenylpropenedithiocarboxylate was equally effective (RPF = 2.6). Finally, methyl 3-morpholino-3-thienyl-2-methylpropenedithiocarboxylate and methyl 3-morpholino-3-(2-pyrazinyl)-2-methylpropenedithiocarboxylate were less effective, producing RPF values of 2.0 and 1.6, respectively. These results demonstrate that several of these compounds are highly effective radioprotectors. In vitro and in vivo studies testing their efficacy are underway.

Citing Articles

Clinical pharmacology studies of oltipraz--a potential chemopreventive agent.

Dimitrov N, Bennett J, McMillan J, Perloff M, Leece C, Malone W Invest New Drugs. 1992; 10(4):289-98.

PMID: 1487402 DOI: 10.1007/BF00944183.

References
1.
Bueding E, Dolan P, Leroy J . The antischistosomal activity of oltipraz. Res Commun Chem Pathol Pharmacol. 1982; 37(2):293-303. View

2.
Teicher B, Rockwell S, Lee J . Radiosensitization of EMT6 cells by four platinum complexes. Int J Radiat Oncol Biol Phys. 1985; 11(5):937-41. DOI: 10.1016/0360-3016(85)90116-6. View

3.
Archer S . The chemotherapy of schistosomiasis. Annu Rev Pharmacol Toxicol. 1985; 25:485-508. DOI: 10.1146/annurev.pa.25.040185.002413. View

4.
De Long M, Dolan P, Santamaria A, Bueding E . 1,2-Dithiol-3-thione analogs: effects on NAD(P)H:quinone reductase and glutathione levels in murine hepatoma cells. Carcinogenesis. 1986; 7(6):977-80. DOI: 10.1093/carcin/7.6.977. View

5.
WATTENBERG L, Bueding E . Inhibitory effects of 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (Oltipraz) on carcinogenesis induced by benzo[a]pyrene, diethylnitrosamine and uracil mustard. Carcinogenesis. 1986; 7(8):1379-81. DOI: 10.1093/carcin/7.8.1379. View